Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Robert Marcus
JPMorgan Chase & Co, Research Division

Good afternoon, everyone. I’m Robbie Marcus, the med tech analyst at JPMorgan. Really happy to present our next speaker, Damien McDonald, CEO of Enovis; along with Ben Berry, the CFO. Damien and Ben are going to do a presentation, and I’ll come up and we’ll do some Q&A afterwards.

Gentlemen?

Damien McDonald
CEO & Director

Thanks, Robbie. Thanks for being here, everyone. My name is Damien. I’m the CEO. I’ve been with Enovis now for about 6 months. So I’m looking forward to some engaging questions. And Ben and I will do a little tag team, talk to you about the company. And then let’s spend as much time as we can on Q&A, and be very interactive with us.

Standard forward-looking harbor — safe harbor statement, so you can read that at your leisure.

Let’s talk a little bit about Enovis. We’re a orthopedics company, but orthopedics was a focus on mobility and the whole continuum of care. I’ll come to that in a minute because it’s been a journey as we’ve built this company over the last sort of 5-ish years through a series of 20-plus acquisitions. We’re around about $2 billion in revenue. We’re growing around about 6%, plus or minus. We just raised our guidance on EBITDA and EPS this morning.

And if you think about the business, it’s roughly 50-50 orthopedics implants and prevention and recovery, and it’s roughly 50-50 international and U.S. And it’s been a journey to build this, and we’re looking forward to telling you